Long‐term effect of rituximab in maintaining remission of recurrent and plasmapheresis‐dependent nephrotic syndrome post‐renal transplantation – Case report

Grenda R, Jarmu?ek W, Pi?tosa B, Rubik J. Long‐term effect of rituximab in maintaining remission of recurrent and plasmapheresis‐dependent nephrotic syndrome post‐renal transplantation – Case report.
Pediatr Transplantation 2011: 15: E121–E125. © 2010 John Wiley & Sons A/S. Abstract: Early recurrence of nephrotic syndrome after renal transplantation is a common serious adverse event in children with severe primary FSGS, affecting long‐term outcome. There is no consensus in terms of uniform management in these cases. We describe the long‐term effect of four unadjusted doses of 375 mg/m² i.v. rituximab, given to a five and a half‐yr‐old, nephrectomized child with immediate recurrence of nephrotic syndrome post‐transplantation and dependency from repeated PF. Rituximab was introduced at three months post‐transplantation after performing 18 sessions of PF and development of established dependency of the disease from plasma exchange. Complete remission of proteinuria was achieved with four doses, and it was maintained during next eight months of follow‐up. Complete B CD₁₉ cell depletion was observed during four months after final dose, followed by severe depletion after eight months. No side effects of therapy were noted. Patient was free from PF, which was stopped while introducing rituximab, remaining non‐proteinuric on triple immunosuppression (CsA, MMF, Pred).